Antiseptic Mouth Rinses to Reduce Salivary Viral Load in COVID-19 Patients

NACompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

June 15, 2020

Primary Completion Date

September 18, 2021

Study Completion Date

September 30, 2021

Conditions
Covid19
Interventions
DRUG

Betadine© bucal 100 mg/ml

15 ml 2% povidone-iodine, one minute rinse.

DRUG

Oximen® 3%

15 ml 1% hydrogen peroxide, one minute rinse.

DRUG

Clorhexidine Dental PHB©

15 ml 0,12% clorhexidine, one minute rinse.

DRUG

Vitis Xtra Forte©

15 ml 0,07% cetylpyridinium chloride, one minute rinse.

DRUG

Distilled Water

15 ml distilled water, one minute rinse.

Trial Locations (1)

46020

Alejandro Mira, Valencia

All Listed Sponsors
collaborator

Hospital Universitario Fundación Jiménez Díaz

OTHER

collaborator

Hospital Universitario General de Villalba

UNKNOWN

collaborator

Hospital Universitario Infanta Elena

UNKNOWN

collaborator

Hospital Universitario Virgen de la Arrixaca

OTHER

collaborator

Hospital Clínico Universitario de Valencia

OTHER

collaborator

Dentaid SL

INDUSTRY

lead

Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana

OTHER

NCT04707742 - Antiseptic Mouth Rinses to Reduce Salivary Viral Load in COVID-19 Patients | Biotech Hunter | Biotech Hunter